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Objective.T oin v estigatetheeﬃcacyofantioxidantsforpreventingpreeclampsiaandothermaternalandfetalcomplicationsamong
pregnant women with low, moderate, or high risk of preeclampsia. Methods. We searched MEDLINE, Embase, CENTRAL, mRCT,
andotherdatabases,withnolanguageorpublicationrestrictions.Twoindependentreviewersselectedrandomizedcontrolledtrials
that evaluated the use of antioxidants versus placebo and extracted the relevant data. Relative risks (RRs) and 95% conﬁdence
intervals (95% CIs) were calculated. The data were compiled through the random eﬀects model. Main Results. Fifteen studies
were included (21,012 women and 21,647 fetuses). No statistically signiﬁcant diﬀerence was found between women who received
antioxidant treatment and women who received placebo for preeclampsia (RR= 0.92; 95% CI: 0.82–1.04), severe preeclampsia
(RR= 1.03; 95% CI: 0.87–1.22), preterm birth (RR= 1.03; 95% CI: 0.94–1.14), and small for gestational age <10th centile (RR=
0.92; 95% CI: 0.80–1.05). Side eﬀects were numerically more frequent in the antioxidants group compared to placebo, but without
signiﬁcant statistical diﬀerence (RR= 1.24; 95% CI: 0.85–1.80). Conclusions. The available evidence reviewed does not support the
use of antioxidants during pregnancy for the prevention of preeclampsia and other outcomes.
1.Introduction
Hypertensive disorders during pregnancy are the most
common cause of maternal death in Latin America and
the Caribbean accounting for 25.7% of all maternal deaths;
in developed countries, the corresponding proportion is
lower, yet still signiﬁcant: 16.1% [1]. Reducing maternal
mortality by three quarters by 2015 is one objective of
the Millennium Development Goals (MDGs) of the United
Nations Development Programme [2].
Although several hypotheses have been proposed, the
causes of preeclampsia remain unclear. There is a relation-
shipbetweenplacentalinsuﬃciencyandthepathophysiology
ofpreeclampsia.Placentaloxidativestressplaysanimportant
role in the manifestations of preeclampsia [3]. Oxidative
stress and lipid peroxidation accompany complications such
as the occurrence of endothelial cell dysfunction in the blood
vessels in women with preeclampsia and other hypertensive
disorders [4, 5]. Antioxidants might be important for the
prevention of lipid peroxidation and, hypothetically, for the
prevention of preeclampsia [3]; however, the evidence of
antioxidants eﬃcacy for preventing preeclampsia has not
been conﬁrmed yet [6, 7].
T h eo b j e c t i v eo ft h i ss t u d yw a st os y s t e m a t i c a l l yr e v i e w
randomized trials of low-, moderate-, or high-risk women
treated with antioxidants to prevent preeclampsia and other
maternal or fetal complications.
2. Methods
2.1. Studies Eligibility Criteria. We considered eligible ran-
domized controlled trials that enrolled women with low,
moderate,orhighriskofpreeclampsiathatusedantioxidants
compared to placebo or no antioxidants, to assess antiox-
idants eﬀect in preeclampsia. If unpublished reports were
detected, we contacted studies’ authors to obtain the data of
interest.
High risk of preeclampsia was deﬁned as previous severe
preeclampsia, diabetes, chronic hypertension, renal disease,
or autoimmune disease. Moderate/low risk was deﬁned as
women who did not meet the criteria for high risk or2 The Scientiﬁc World Journal
have ﬁrst pregnancy, a mild rise in blood pressure and
no proteinuria, positive roll-over test, abnormal uterine
artery Doppler scan, multiple pregnancy, a family history
of preeclampsia, maternal age less than 20, and known
thrombophilia. When the risk was unclear or unspeciﬁed,
women were classiﬁed as moderate/low risk [6].
2.2. Sources and Search Strategies. Literature search was
performed with no language restrictions and no limits on
publication date. The research was done on MEDLINE,
Embase, Cochrane Central Register of Controlled Trials
(CENTRAL), metaRegister of Controlled Trials (mRCT),
Centre for Reviews and Dissemination (CDR), ISI of Web
Science, Scopus, Latin American and Caribbean Center
on Health Sciences Information (LILACS), and Scientiﬁc
Electronic Library Online (SciELO) databases. References
from relevant studies were also researched to identify
potentially eligible studies. To identify the grey literature,
ProQuest Dissertation and Theses and Brazilian theses
registration databases were searched, as well as websites of
gynecology and obstetrics associations. Last literature search
was performed in October 2011.
Search strategy used in MEDLINE (via PubMed) was
((“preeclampsia” [mesh] or “pre-eclampsia” [tiab] or pre-
eclampsia [tiab] and “pregnancy complications” [mesh] or
“pregnancy” [mesh] or “pregnancy” [tiab]) and (“antiox-
idants” [tiab] or “antioxidants” [mesh] or “antioxidants”
[pharmacological action] or “antioxidant” [tiab]) or “a-
scorbic acid” [mesh] or “ascorbic acid” [tiab] or “a-
scorbic acid” [tiab] or “vitamin c” [tiab] or “vitamin e”
[mesh] or “vitamin e” [tiab] or “alpha-tocopherol” [mesh]
or alphatocopherol [tiab] or “beta carotene” [mesh] or
“betacarotene” [tiab] or “selenium” [mesh] or selenium
[tiab] or “glutathione peroxidase” [mesh] or “glutathione
peroxidase” [tiab] or “superoxide dismutase” [mesh] or “su-
peroxide dismutase” [tiab] or “catalase” [mesh] or “cat-
alase” [tiab]) and (therapy/narrow [ﬁlter]). We adapted this
strategy for searching on the other databases.
2.3. Studies Selection. Two reviewers (LDCM, AMRS)
selected the articles in an independent, unblinded manner,
by reading the studies’ titles and abstracts. Cases of disagree-
ment were resolved in consensus meetings.
2.4. Data Extraction. Two reviewers (LDCM, AMRS)
extracted data independently on a purpose-built electronic
form. In the event of disagreement, the decision was taken
by reaching a consensus or by an independent reviewer
(TFG). We extracted from studies the year, country, fund-
ing source, type of study, sample size, group allocation,
population characteristic, intervention, primary outcomes
and secondary outcomes. We contacted the corresponding
author of included studies if any data were not available in
the paper.
2.5. Quality and Risk of Bias Assessments. This assessment
was made independently by two reviewers (LDCM, AMRS),
using the Cochrane Collaboration method [8]. We evaluated
the following items: random sequence generation, alloca-
tion concealment, blinding of participants and personnel,
blinding of outcome assessment, incomplete outcome data,
selective reporting, and other bias (such as an insensitive
instrument used to measure outcomes, selective reporting of
subgroupsandbaselineimbalanceinfactorsthatarestrongly
related to outcome).
Sensitivity analysis of the global eﬀect was conducted to
verify the impact of studies of lower quality on the primary
outcome: such studies were excluded from the analysis and
the results were compared to the full analysis.
Funnel plot asymmetry was assessed and grey literature
search was included to minimize the risk of publication bias
[8]. We also calculated Peters’ test for small-study eﬀects [9]
and Harbord’s modiﬁed test for small-study eﬀects [10]t o
objectively detect publication bias.
Excluded studies due to full text not being available were
included in primary outcome meta-analysis to assess their
impact on global eﬀect, publication bias, and heterogeneity
(sensitivity analysis).
2.6. Outcomes. The primary outcome measured was the
relative risk (RR) of preeclampsia. Secondary outcomes
were severe preeclampsia (including HELLP syndrome—
hemolysis, elevated liver enzymes, and low platelet count,
and imminent eclampsia), preterm birth (less than 37
completed weeks of pregnancy), small for gestational age
infants (deﬁned as smaller than the third, smaller than the
ﬁfth, and smaller than the tenth percentile), and baby death
(miscarriage, stillbirth, neonatal, and infant death). The
incidence of side eﬀects was also veriﬁed.
2.7. Statistical Analysis. Statistical analysis was based on the
calculated relative risks and their respective 95% conﬁdence
intervals (95% CI) for each study reviewed. The data from
all the studies were compiled based on the Mantel-Haenszel
test, through the random eﬀects model. Analysis and graphs
wereobtainedbyusingReviewManager5(version5.1.6)and
STATA (version 10.1). The chi-squared tests (P ≤ 0.10), I
2,
and Tau2 were calculated to assess heterogeneity among the
studies. Studies with moderate or substantial heterogeneity
were explored to identify possible causes for inconsistency
[8]. If absolute values were absent, we calculated them from
relative results available on the reports.
3. Results
A total of 4,231 studies were retrieved and 15 were included
in our analysis (Figure 1). All studies were randomized
placebo-controlled trials that assessed including 21,012
women and 21,647 fetuses. The main characteristics of
included studies are shown in Table 1.
3.1. Quality and Risk of Bias Assessments. Quality assessment
result is shown in Figure 2. Three articles satisﬁed all quality
assessment criteria [8, 27, 28]. In all the items analyzed,
at least ∼50% of the articles presented a low risk of bias.The Scientiﬁc World Journal 3
Scopus (n = 128)
Embase (n = 101)
ProQuest (n = 66) ISI Web (n = 36)
mRCT (n = 13)
SciELO (n = 6) CRD (n = 3)
Duplicates (n = 224)
Studies assessed for eligibility
Studies not meeting
eligibility criteria
Studies selected for full text
assessment (n = 26)[11-36]
Did not report primary outcome (n = 4)[11-14]
Intervention not suitable for review (n = 1)[15]
Not RCT (n = 2)[16, 17]
Studies retrieved from the database search (n = 4.231)
MEDLINE (n = 1.585)
CENTRAL (n = 26)
LILACS (n = 7)
(n = 4.007)
(n = 3.981)
Theses registration database (n = 2)
Excluded studies (n = 11):
Full text not available (n = 2)[20, 21]
Articles included in the review (n = 15)[22-36]
Patients losses graeter than 30% (n = 2)[18, 19]
Figure 1: Flow chart of the search, selection, and inclusion of studies.4 The Scientiﬁc World Journal
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Figure 3:Preeclampsiaincidenceproportionwithantioxidantsand
placebo groups.
Roughly 30% of the articles presented a high risk of bias on
the items: incomplete outcome data [29, 31, 34], selective
reporting [26, 31, 34, 35], and other bias [23, 24, 33], that
included insensitive instrument used to measure outcomes
and deviation from the study protocol.
Inspection of the funnel plots for preeclampsia medical
outcome (data not presented) revealed asymmetric results,
indicating a risk of publication bias. This risk was found to
be statistically signiﬁcant by Peters’ test (P = 0.005) and
Harbord’s modiﬁed test (P = 0.004) for small-study eﬀects.
We found a higher number of smaller studies that favored
antioxidants, suggesting that similar studies that favored
control group were not published. In Figure 3,aL ’ A b b ´ e
plot, each trial is represented by a circle whose diameter
is proportional to the population size. Larger studies are
located along the no diﬀerence line (RR = 1), while smaller
studies show worse results with placebo group.
Several studies did not report any side eﬀects. This could
be considered selective reporting bias. It was not possible to
obtain the protocols of these randomized controlled trials
to check whether reporting this outcome was planned. The
authors may not have considered the incidence of side eﬀects
asarelevantoutcomeandthusrefrainedfromcollectingsuch
data. Due to these uncertainties, the omission of side eﬀects
on studies results was not considered as selective reporting.
Two studies did not publish their data in full text, just as
conference abstracts [20, 21], what prevented us to perform
their quality assessment and the studies were excluded from
analysis (Figure 1). Sensitivity analysis was done to assess
such exclusion impact on publication bias. By including
these studies in the paper, the asymmetry of the funnel plot
increased, as well as heterogeneity of preeclampsia outcome
(Chi2 28.88, df 15 (P = 0.02); I
2 45%). Furthermore, the risk
of preeclampsia was numerically lower (RR = 0.90; 95% CI:
0.78–1.03).
3.2. Outcomes. There was no statistically signiﬁcant diﬀer-
ence for preeclampsia incidence when comparing women
who received antioxidants and the placebo group (n =
21,012; RR = 0.92; 95% CI: 0.82–1.04; Figure 4). Only two
studies revealed a signiﬁcant result of reduced occurrence
preeclampsia in the group of women who used antioxidant
compared to the placebo group [23, 24]. No diﬀerence was
noted in severe preeclampsia (n = 16,341; RR = 1.03; 95%
CI: 0.87–1.22; Figure 4).
Preterm birth, small for gestational age <3rd centile,
small for gestational age <5th centile, small for gestational
age <10th centile, miscarriage, and neonatal death were also
found not to be statistically signiﬁcant (Table 2).The Scientiﬁc World Journal 7
Id Year n
Han
Chappell
Beazley
Steyn
Sharma
Rumbold
Poston
Rumiris
Banerjee
Villar
Spinnato
Xu
McCance
Roberts
Vadillo-Ortega
Severe pre-eclampsia
Banerjee
Beazley
Poston
Villar
Xu
Side-eﬀects
Banerjee
Rumbold
Spinnato
Roberts
1994
1999
2003
2003
2006
2006
2006
2009
2009
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11 7 6
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707
9969
2009
2006
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Table 2: Fetal outcomes meta-analysis and heterogeneity results. Comparison: antioxidants versus placebo.
Outcome Studies Population size Pooled RR 95% CI P value Heterogeneity tests
Chi2P value I
2 Tau2
Preterm birth 13 21,166 1.03 0.94–1.14 0.51 0.05 43.9% 0.01
Small for gestational age <3rd centile 2 11,634 0.85 0.56–1.30 0.46 0.12 57.9% 0.06
Small for gestational age <5th centile 2 5,320 1.06 0.88–1.28 0.54 0.21 37.6% 0.01
Small for gestational age <10th centile 8 9,672 0.92 0.80–1.05 0.22 0.06 49.2% 0.02
Miscarriage or stillbirth 8 9,209 1.17 0.79–1.74 0.44 0.14 35.6% 0.11
Neonatal death 8 19,135 0.79 0.54–1.17 0.24 0.88 0.0% 0.00
The estimates of preterm birth and small for gestational
age infants were heterogeneous. Analysis of this heterogene-
ity causes showed that it is probably due to diﬀerences in
population [32, 33] and interventions [31, 35].
Women who took antioxidants presented an increased
numberofsideeﬀectscomparedtowomenwhotookplacebo
but no statistically signiﬁcant diﬀerence between the groups
analyzed was identiﬁed (n = 12,580; RR = 1.24; 95%
CI: 0.85–1.80). Reported eﬀects were abdominal pain at
the end of pregnancy [28, 30]: itching, eczema, vomiting,
diarrhea, headache, constipation, malaise, decreased vision
[30], skin rash, and chest pain [31]. One study reported
nauseaandvomitingassideeﬀects[34].Toavoidduplication
of participants, we only included nausea data in the meta-
analysis. Another trial reported no occurrence of side eﬀects
but only assessed changes in blood and urine analysis or in
liverorrenalfunction[34].Thepolledestimateofsideeﬀects
showed to be heterogeneous. Exploring this heterogeneity
we noticed clinical and methodological diﬀerences across
studies.
The sensitivity analysis of the primary outcome consid-
ering only studies that fulﬁlled all quality criteria (Poston
2006 [27], Rumbold et al. 2006 [28], and Villar et al. 2009
[32])revealedanonsigniﬁcantincreasedriskofpreeclampsia
(n = 5,627; RR = 1.02; 95% CI: 0.90–1.16; heterogeneity:
Chi2P value = 0.60; I
2
= 0%).
4. Discussion
Antioxidants eﬃcacy for preventing preeclampsia was not
observed from included studies and results from these
studies are prone to have publication bias, what reduces the
conﬁdence of the ﬁndings. Only two isolated studies showed
a signiﬁcant reduction of preeclampsia in women treated
with antioxidants compared to placebo, but important
diﬀerences were present, mainly on interventions. Eﬃcacy
was also not detected for other outcomes assessed. The large
number of women randomly investigated leads us to believe
that additional studies would probably not alter this result.
The sensitivity analysis, when including only studies that
met all quality criteria, revealed a nonsigniﬁcant increased
risk of preeclampsia, while the analysis including all studies
reduced the risk, also without statistically signiﬁcant diﬀer-
ence between antioxidants and placebo.
Heterogeneity across studies was not signiﬁcant for
the outcomes preeclampsia, severe preeclampsia, or baby
death. Moderate heterogeneity was found for small for
gestational age, preterm birth and side eﬀects. This may
have been due to clinical and methodological diﬀerences
identiﬁed in some of the studies. However, due to their large
sample size, heterogeneity tests can identify small statistical
heterogeneous portions that may not be clinically important
[8].
4.1. Previous Systematic Reviews. We found seven systematic
reviews that analyzed the eﬃcacy of antioxidants in the
prevention of preeclampsia and other maternal and fetal
outcomes [6, 7, 37–41]. Five reviews showed no statically
signiﬁcant diﬀerence for the outcomes analyzed [6, 7, 39–
41]. Of these, four tested the eﬃcacy of the combination
of vitamins C and E [7, 39–41]. One review assessed the
eﬃcacy of any antioxidant and found no statically signiﬁcant
diﬀerenceintheassessedoutcomes,exceptforthesideeﬀects
[6].
Another review assessed only vitamin C as antioxidant
and showed a higher risk of preterm birth in women who
took vitamin C compared to placebo group, but a lower risk
of preeclampsia in those treated with antioxidant [37]. Other
outcomes were not statistically signiﬁcant. Meanwhile, the
reviewthatanalyzedonlyvitaminEalsofoundalowerriskof
preeclampsia among the group who took the vitamin versus
placebo, with no statically signiﬁcant diﬀerence from other
outcomes [38]. Despite these reviews stated to analyze only
vitamin C or E eﬀects, other antioxidants were included and
the total number of included women was less than 1,000 in
both reviews, thus showing small precision.
O n es t u d yp e r f o r m e ds u b g r o u pr i s ka n a l y s i sf o r
preeclampsia to test the antioxidant eﬀect [39]. No statis-
tically signiﬁcant diﬀerences between analyzed groups were
found.
4.2. Strengths and Limitations of the Review. This review
presents a method in line with the current recommendations
for systematic reviews: sensitive search, no restrictions on
language or publication date, search for grey literature,
paired selection, and data extraction [8, 42]. Such measures
are required to avoid biases and reveal transparent and
faithful results.
Furthermore, meta-analyses were conducted following
the random eﬀects model. The results were subjected to
sensitivity analysis and assessment of publication bias andThe Scientiﬁc World Journal 9
heterogeneityacrossresults.Thisprocedureaimedtoidentify
and explain possible biases.
Althoughtwostudieswereexcludedduetoabsenceoffull
text, we assessed the impact of their exclusion on the funnel
plot asymmetry, heterogeneity, and outcome estimates. It
was shown that the inclusion of these studies would not lead
to important change in the results.
We intended to test the eﬃcacy of any antioxidants
because other systematic reviews had shown nonsigniﬁcant
results for vitamin C and E for preventing preeclampsia. As
most randomized controlled trials only analyzed these two
vitamins, such studies inﬂuenced the results, rending not
suﬃcient data to test the eﬃcacy of other antioxidants than
vitamin C and E.
There are a reasonable number of studies that verify
the eﬃcacy of antioxidants for preventing preeclampsia,
resulting in a large number of women assessed. The number
ofincluded patients inourreviewwasthreetimes largerthan
the last Cochrane Review that also reviewed the eﬃcacy of
any kind of antioxidants [6], what is likely to imply in greater
precision in the analysis.
5. Conclusion
Available evidence does not support the use of antioxidants
during pregnancy. Their use in pregnancy for the prevention
of preeclampsia and other maternal and fetal outcomes
should be well balanced, as beneﬁcial eﬀects are not proved.
Conﬂict of Interests
The authors declare that they have no conﬂict of interests.
Acknowledgments
The authors especially thank Dr. Alvin Charles Bronstein
for reviewing the ﬁnal version of the paper. This research
was funded by public research grant from Brazilian National
Research Council (CNPq).
References
[1] K.S.Khan,D.Wojdyla,L.Say,A.M.G¨ ulmezoglu,andP.F.van
Look,“WHOanalysisofcausesofmaternaldeath:asystematic
review,” The Lancet, vol. 367, no. 9516, pp. 1066–1074, 2006.
[2] MDGR Millennium Development Goals Report 2010, United
Nations Department of Economic and Social Aﬀairs, New
York, NY, USA, 2010.
[3] M.T.Raijmakers,R.Dechend,andL.Poston,“Oxidativestress
and preeclampsia: rationale for antioxidant clinical trials,”
Hypertension, vol. 44, no. 4, pp. 374–380, 2004.
[ 4 ] H .O r h a n ,L .O n d e r o g l u ,A .Y¨ ucel, and G. Sahin, “Circulating
biomarkers of oxidative stress in complicated pregnancies,”
Archives of Gynecology and Obstetrics, vol. 267, no. 4, pp. 189–
195, 2003.
[5] A. M. Roggensack, Y. Zhang, and S. T. Davidge, “Evidence
for peroxynitrite formation in the vasculature of women with
preeclampsia,” Hypertension, vol. 33, no. 1 I, pp. 83–89, 1999.
[ 6 ]A .R u m b o l d ,L .D u l e y ,C .A .C r o w t h e r ,a n dR .R .H a s l a m ,
“Antioxidants for preventing pre-eclampsia,” Cochrane
Database of Systematic Reviews, no. 1, Article ID CD004227,
2008.
[7] N. P. Polyzos, D. Mauri, M. Tsappi et al., “Combined vitamin
C and E supplementation during pregnancy for preeclampsia
prevention: a systematic review,” Obstetrical and Gynecological
Survey, vol. 62, no. 3, pp. 202–206, 2007.
[8] J. Higgins and S. Green, Eds., Cochrane Handbook for Sys-
tematic Reviews of Interventions, Version 5.1.0 edition, 2011,
http://www.cochrane-handbook.org.
[ 9 ] J .L .P e t e r s ,A .J .S u t t o n ,D .R .J o n e s ,K .R .A b r a m s ,
and L. Rushton, “Comparison of two methods to detect
publication bias in meta-analysis,” Journal of the American
Medical Association, vol. 295, no. 6, pp. 676–680, 2006.
[10] R. M. Harbord, M. Egger, and J. A. Sterne, “A modiﬁed test for
small-study eﬀects in meta-analyses of controlled trials with
binary endpoints,” Statistics in Medicine, vol. 25, no. 20, pp.
3443–3457, 2006.
[11] N. Bhatla, N. Kaul, N. Lal et al., “Comparison of eﬀect of daily
versusweeklyironsupplementationduringpregnancyonlipid
peroxidation,” Journal of Obstetrics and Gynaecology Research,
vol. 35, no. 3, pp. 438–445, 2009.
[12] J. Mier-Cabrera, M. Genera-Garc´ ıa, J. de la Jara-D´ ıaz,
O. Perichart-Perera, F. Vadillo-Ortega, and C. Hern´ andez-
Guerrero, “Eﬀect of vitamins C and E supplementation on
peripheral oxidative stress markers and pregnancy rate in
women with endometriosis,” International Journal of Gynecol-
ogy and Obstetrics, vol. 100, no. 3, pp. 252–256, 2008.
[13] A. T. Merchant, G. Msamanga, E. Villamor et al., “Mul-
tivitamin supplementation of HIV-positive women during
pregnancy reduces hypertension,” Journal of Nutrition, vol.
135, no. 7, pp. 1776–1781, 2005.
[14] E. Casanueva, C. Ripoll, M. Tolentino et al., “Vitamin
C supplementation to prevent premature rupture of the
chorioamniotic membranes: a randomized trial,” American
Journal of Clinical Nutrition, vol. 81, no. 4, pp. 859–863, 2005.
[ 1 5 ]H .J u ,A .R .R u m b o l d ,K .J .W i l l s o n ,a n dC .A .C r o w t h e r ,
“Borderline gestational diabetes mellitus and pregnancy out-
comes,”BMCPregnancyandChildbirth,vol.8,article31,2008.
[16] O.Perichart-Perera,M.Balas-Nakash,A.Parra-Covarrubiaset
al., “A medical nutrition therapy program improves perinatal
outcomes in Mexican pregnant women with gestational
diabetes and type 2 diabetes mellitus,” Diabetes Educator, vol.
35, no. 6, pp. 1004–1013, 2009.
[17] S.Bond,“VitaminsCandEdonothelppreventpreeclampsia,”
JournalofMidwiferyandWomen’sHealth,vol.53,no.2,p.169,
2008.
[ 1 8 ] F .T a r a ,G .M a a m o u r i ,M .P .R a y m a ne ta l . ,“ S e l e n i u ms u p p l e -
mentation and the incidence of preeclampsia in pregnant Ira-
nian women: a randomized, double-blind, placebo-controlled
pilottrial,”TaiwaneseJournalofObstetricsandGynecology,vol.
49, no. 2, pp. 181–187, 2010.
[19] E. Teran, I. Hernandez, B. Nieto, R. Tavara, J. E. Ocampo, and
A. Calle, “Coenzyme Q10 supplementation during pregnancy
reduces the risk of pre-eclampsia,” International Journal of
Gynecology and Obstetrics, vol. 105, no. 1, pp. 43–45, 2009.
[20] Z. A. Mahdy, H. H. Siraj, M. H. Azwar et al., “The role of
palm oil vitamin E in the prevention of pregnancy-induced
hypertension,” Hypertension in Pregnancy, vol. 23, p. 67, 2004.
[21] C. A. Rivas-Echeverria, Y. Echeverria, L. Molina, and D.
Novoa, “Synergic use of aspirin, ﬁsh oil and vitamins C
and E for the prevention of preeclampsia,” Hypertension in
Pregnancy, vol. 19, supplement 1, p. 30, 2000.10 The Scientiﬁc World Journal
[22] L. Han and S. M. Zhou, “Selenium supplement in the pre-
vention of pregnancy induced hypertension,” Chinese Medical
Journal, vol. 107, no. 11, pp. 870–871, 1994.
[ 2 3 ]L .C .C h a p p e l l ,P .T .S e e d ,A .L .B r i l e ye ta l . ,“ E ﬀect of
antioxidants on the occurrence of pre-eclampsia in women at
increased risk: a randomised trial,” The Lancet, vol. 354, no.
9181, pp. 810–816, 1999.
[24] J. B. Sharma, A. Kumar, M. Malhotra, R. Arora, S. Prasad,
and S. Batra, “Eﬀect of lycopene on pre-eclampsia and intra-
uterine growth retardation in primigravidas,” International
Journal of Gynecology and Obstetrics, vol. 81, no. 3, pp. 257–
262, 2003.
[25] P. S. Steyn, H. J. Odendaal, J. Schoeman, C. Stander, N.
Fanie, and D. Grov´ e, “A randomised, double-blind placebo-
controlled trial of ascorbic acid supplementation for the
prevention of preterm labour,” J o u r n a lo fO b s t e t r i c sa n d
Gynaecology, vol. 23, no. 2, pp. 150–155, 2003.
[26] D. Beazley, R. Ahokas, J. Livingston, M. Griggs, and B.
M. Sibai, “Vitamin C and E supplementation in women at
high risk for preeclampsia: a double-blind, placebo-controlled
trial,” American Journal of Obstetrics and Gynecology, vol. 192,
no. 2, pp. 520–521, 2005.
[27] L.Poston,A.L.Briley,P.T.Seed,F.J.Kelly,andA.H.Shennan,
“Vitamin C and vitamin E in pregnant women at risk for pre-
eclampsia (VIP trial): randomised placebo-controlled trial,”
The Lancet, vol. 367, no. 9517, pp. 1145–1154, 2006.
[28] A. R. Rumbold, C. A. Crowther, R. R. Haslam, G. A. Dekker, J.
S. Robinson, and ACTS Study Group, “Vitamins C and E and
the risks of preeclampsia and perinatal complications,” New
England Journal of Medicine, vol. 354, no. 17, pp. 1796–1806,
2006.
[29] D. Rumiris, Y. Purwosunu, N. Wibowo, A. Farina, and
A. Sekizawa, “Lower rate of preeclampsia after antioxidant
supplementation in pregnant women with low antioxidant
status,” Hypertension in Pregnancy, vol. 25, no. 3, pp. 241–253,
2006.
[30] J. A. Spinnato, S. Freire, J. L. Pinto e Silva et al., “Antioxidant
therapy to prevent preeclampsia: a randomized controlled
trial,” Obstetrics and Gynecology, vol. 110, no. 6, pp. 1311–
1318, 2007.
[31] S. Banerjee, S. Jeyaseelan, and R. Guleria, “Trial of lycopene to
prevent pre-eclampsia in healthy primigravidas: results show
some adverse eﬀects,” Journal of Obstetrics and Gynaecology
Research, vol. 35, no. 3, pp. 477–482, 2009.
[32] J. Villar, M. Purwar, M. Merialdi et al., “World Health Organ-
isation multicentre randomised trial of supplementation with
vitamins C and e among pregnant women at high risk for
pre-eclampsia in populations of low nutritional status from
developing countries,” An International Journal of Obstetrics
and Gynaecology, vol. 116, no. 6, pp. 780–788, 2009.
[33] D. R. McCance, V. A. Holmes, M. J. Maresh et al., “Vitamins C
and E for prevention of pre-eclampsia in women with type 1
diabetes(DAPIT):arandomisedplacebo-controlledtrial,”The
Lancet, vol. 376, no. 9737, pp. 259–266, 2010.
[34] J.M.Roberts,L.Myatt,C.Y.Spongetal.,“VitaminsCandEto
prevent complications of pregnancy-associated hypertension,”
New England Journal of Medicine, vol. 362, no. 14, pp. 1282–
1291, 2010.
[35] H. Xu, R. Perez-Cuevas, X. Xiong et al., “An international trial
of antioxidants in the prevention of preeclampsia (INTAPP),”
American Journal of Obstetrics and Gynecology, vol. 202, no. 3,
pp. 239.e1–239.e10, 2010.
[36] F. Vadillo-Ortega, O. Perichart-Perera, S. Espino et al., “Eﬀect
of supplementation during pregnancy with L-arginine and
antioxidantvitaminsinmedicalfoodonpre-eclampsiainhigh
risk population: randomised controlled trial,” British Medical
Journal, vol. 342, no. 7808, Article ID d2901, 2011.
[37] A.RumboldandC.A.Crowther,“VitaminCsupplementation
in pregnancy,” Cochrane Database of Systematic Reviews,n o .2 ,
Article ID CD004072, 2005.
[38] A. Rumbold and C. A. Crowther, “Vitamin E supplementation
in pregnancy,” Cochrane Database of Systematic Reviews,n o .2 ,
Article ID CD004069, 2005.
[39] A. Conde-Agudelo, R. Romero, J. P. Kusanovic, and S. S.
Hassan, “Supplementation with vitamins C and E during
pregnancy for the prevention of preeclampsia and other
adverse maternal and perinatal outcomes: a systematic review
andmetaanalysis,”AmericanJournalofObstetricsandGynecol-
ogy, vol. 204, no. 6, pp. 503.e1–503.e12, 2011.
[40] A. Basaran, M. Basaran, and B. Topatan, “Combined vitamin
C and E supplementation for the prevention of preeclampsia:
a systematic review and meta-analysis,” Obstetrical and Gyne-
cological Survey, vol. 65, no. 10, pp. 653–667, 2010.
[41] A. C. Rossi and P. M. Mullin, “Prevention of pre-eclampsia
with low-dose aspirin or vitamins C and e in women at high
or low risk: a systematic review with meta-analysis,” European
Journal of Obstetrics Gynecology and Reproductive Biology, vol.
158, no. 1, pp. 9–16, 2011.
[42] Centre for Reviews and Dissemination, Systematic Reviews:
CRD’s Guidance for Undertaking Reviews in Health Care, 2009.